Praluent Regret, Stopping, and Restarting: What Real Patients and Clinical Data Show

Does the label warn about stopping Praluent?

The Praluent label has no boxed warning. Its only Warning and Precaution is hypersensitivity reactions, including hypersensitivity vasculitis, angioedema and reactions requiring hospitalization; the label says to discontinue treatment and treat according to the standard of care if serious symptoms occur [1]. A history of a serious hypersensitivity reaction to alirocumab or any excipient is a contraindication [1].

What happens as alirocumab clears?

Alirocumab binds PCSK9, the protein that promotes degradation of LDL receptors on liver cells; blocking that binding leaves more LDL receptors available to clear LDL from the blood [1]. After a single 75 mg or 150 mg injection, free PCSK9 was maximally suppressed within 4 to 8 hours, and it returned to baseline when alirocumab concentrations fell below the limit of quantitation [1].

Clearance is slow: the median apparent half-life at steady state is 17 to 20 days [1]. In ODYSSEY OUTCOMES, 730 participants (7.7%) were switched from Praluent to placebo in a blinded fashion after two consecutive LDL-C values under 15 mg/dL [1].

Why people stopped in trials

Across nine placebo-controlled trials (2,476 on Praluent, 1,276 on placebo, median 65 weeks), 5.3% on Praluent and 5.1% on placebo stopped for adverse reactions. The leading causes were allergic reactions (0.6% vs 0.2%) and elevated liver enzymes (0.3% vs under 0.1%) [1]. Injection site reactions were 7% vs 5% and myalgia 4% vs 3% [1].

Missed doses and dosing

The label says that if a dose is missed, it can be given within 7 days of the missed date and the original schedule resumed. If more than 7 days late, on the every-2-week schedule the patient waits for the next scheduled dose; on the every-4-week schedule the dose is given and a new schedule starts from that date [1].

For reference, the label's starting doses for adults with hypercholesterolemia are 75 mg every 2 weeks or 300 mg every 4 weeks, adjusted to 150 mg every 2 weeks if the LDL-C response is inadequate. The label says LDL-C lowering may be measured as early as 4 weeks after initiation [1].

What the main outcomes trial showed

ODYSSEY OUTCOMES enrolled 18,924 adults who had an acute coronary syndrome 1 to 12 months earlier [3]. Over a median follow-up of 2.8 years [3], the primary cardiovascular outcome occurred in 9.5% on Praluent vs 11.1% on placebo, HR 0.85 (95% CI 0.78 to 0.93) [1]. All-cause death was 3.5% vs 4.1% and was not statistically significant under the prespecified testing method [1].